Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Notes Payables (2019 - 2025)

Bioadaptives' Notes Payables history spans 7 years, with the latest figure at $32096.0 for Q4 2025.

  • On a quarterly basis, Notes Payables changed 0.0% to $32096.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $32096.0, a 0.0% change, with the full-year FY2025 number at $32096.0, changed 0.0% from a year prior.
  • Notes Payables hit $32096.0 in Q4 2025 for Bioadaptives, down from $359300.0 in the prior quarter.
  • Over the last five years, Notes Payables for BDPT hit a ceiling of $423888.0 in Q3 2022 and a floor of $10246.0 in Q2 2022.
  • Historically, Notes Payables has averaged $186765.2 across 5 years, with a median of $177357.5 in 2021.
  • Biggest five-year swings in Notes Payables: tumbled 95.01% in 2022 and later soared 2981.57% in 2023.
  • Tracing BDPT's Notes Payables over 5 years: stood at $33715.0 in 2021, then surged by 1032.41% to $381793.0 in 2022, then decreased by 15.75% to $321658.0 in 2023, then crashed by 90.02% to $32096.0 in 2024, then changed by 0.0% to $32096.0 in 2025.
  • Business Quant data shows Notes Payables for BDPT at $32096.0 in Q4 2025, $359300.0 in Q3 2025, and $311000.0 in Q2 2025.